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Abstract 
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder caused by dystrophin 
loss—notably within muscles and CNS neurons. DMD presents as cognitive weakness, 
progressive skeletal and cardiac muscle degeneration until pre-mature death from cardiac or 
respiratory failure. Innovative therapies improved life expectancy, but this is accompanied by 
increased late-onset heart failure and emergent cognitive degeneration. Thus, there is an 
increasing need to both better understand and track disease pathophysiology in the dystrophic 
heart and brain prior to onset of severe degenerative symptoms. Chronic inflammation is strongly 
associated with skeletal and cardiac muscle degeneration, however chronic neuroinflammation’s 
role is largely unknown in DMD despite being prevalent in other neurodegenerative diseases. 
Considering the well-known consequences of unchecked chronic inflammation, inflammation’s 
contribution towards multi-organ degeneration must be explored. Thus, this study explored 
inflammatory marker translocator protein positron emission tomography (TSPO-PET) to 
evaluate immune cell infiltration within the hearts and brains of DMD murine models. Four 
DMD and six healthy mice underwent whole-body PET imaging using the TSPO radiotracer 
[18F]FEPPA. Confirmatory TSPO-immunofluorescence staining of cardiac and neural tissues 
were also conducted. Our results indicated that DMD mice showed significant elevations in heart 
and brain [18F]FEPPA activity, which correlated with increased ex-vivo fluorescence intensity. In 
summary, this study suggests cardiac and neuroinflammation presence in DMD and highlights 
TSPO-PET’s utility as a tool for in-vivo assessment of inflammation in several organs 
simultaneously within DMD.  
Keywords 
Duchenne muscular dystrophy, [18F]FEPPA, positron emission tomography, neuroinflammation, 
cardiac inflammation, mdx:utrn(+/-) 
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Summary for Lay Audience 
Duchenne muscular dystrophy is characterized by progressive skeletal and heart 
weakness, and cognitive impairment. Current therapies have increased patient longevity, 
revealing the emergence of heart and brain degenerative symptoms at the later stages of the 
disease. Thus, there is a need to better assess, understand, and track the potential sources of 
multi-organ dysfunction in DMD. Inflammation is thought to be a prime contributor to these 
dysfunctions because it is widespread in both the DMD patient’s muscle and blood. However, 
not much is known about inflammation in the brain of DMD subjects. This work addresses this 
gap in knowledge through the assessment of inflammation in the brains and hearts of DMD mice 
using live animal imaging and tissue measurements of [18F]FEPPA, a radiotracer that 
accumulates in inflammatory cells. We found higher [18F]FEPPA in the hearts and brains of 
DMD mice compared to healthy mice. This research demonstrates that imaging using 
[18F]FEPPA can be a useful tool to assess inflammation in multiple organs in live mice models of 
DMD. 
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Chapter 1  
1 Introduction 
1.1 Clinical Symptoms of Duchenne Muscular Dystrophy 
1.1.1 Overview 
Duchenne muscular dystrophy (DMD) is a fatal progressive neuromuscular disorder that 
affects approximately 1 in 3600 males worldwide, becoming the most commonly 
inherited pediatric muscle dystrophy. DMD is typically caused by a X-linked recessive 
mutation in the DMD gene, resulting in a higher emergence of pathological symptoms in 
males than females [1]. However, DMD can also occur as a result of new spontaneous de 
novo mutations, which are thought to occur in approximately one-third of affected boys, 
while the remaining cases are attributed to the mutation inheritance from their carrier 
mothers [2,3]. Dystrophin proteins are present in several tissue types, but most notably 
are found within skeletal muscle, cardiac muscle, neurons within the central nervous 
system (CNS). In most cases, DMD is characterized by muscle weakness and 
degeneration, alongside cognitive impairment. These symptoms are often exacerbated by 
chronic inflammation, and ischemia, often followed by fibrosis until the patient succumbs 
to an early death from cardiac or respiratory complications [4–6]. Although there is still 
no cure, recent advancements in experimental therapies have prolonged both ambulation 
and life expectancy to approximately ages 30-40 [6,7].   
1.1.2 Life phases  
Infant DMD boys are asymptomatic as the first noticeable symptoms often manifest at 2-
5 years, resulting in a late average age of definitive diagnosis at 5 years old. At this time, 
affected boys typically present lower limb and trunk muscle weakness before substantial 
muscular deterioration—causing gait problems, calf hypertrophy, Gower’s sign, and 
other orthopedic complications between the ages of 6-8. By the onset of puberty, the 
majority of these affected patients will lose a substantial amount of motor function and 
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become wheelchair-bound—by the age of 10-12—before cardiac and respiratory function 
begin to deteriorate. The loss of respiratory muscular structures results in decreased 
pulmonary function, increasing the likelihood of developing respiratory infection and 
failure by age 20 [1,8,9]. Currently, developments in skeletal muscle treatments (e.g. 
corticosteroids, gene therapies, etc.) and respiratory care (e.g. use of respiratory assist 
devices, non-invasive ventilation, etc.) have had success in prolonging ambulation and 
life expectancy of patients—increasing the average age of mortality from 15-19 to 30-35 
[10,11]. However, with these increases in longevity, cardiac dysfunction has become the 
major cause of morbidity in DMD patients [12].  
1.1.3 Clinical Symptoms of the Dystrophic Heart  
Cardiovascular complications in DMD— typically dilated cardiomyopathy and cardiac 
arrhythmia—become detectable when the child reaches 10-12 years of age. A common 
misconception is that the dystrophic heart is clinically silent until the patient reaches 
puberty. However, pre-clinical signs of cardiomyopathy within patients—as young as 6 
years of age—are abundant including sinus tachycardia and associated electrocardiograph 
abnormalities, right ventricle hypertrophy, and wall motion abnormalities in 
electrocardiograms. Around the age of 9-10, the first detectable signs of clinical 
cardiomyopathy emerge as myocardial fibrosis and left ventricle enlargement, which is 
then followed by ventricular dilation and dysfunction. From 10 years of age onwards, 
there is a rapid progression of both cardiac dysfunction severity and prevalence [6,13]. 
The number of cardiomyopathy symptomatic DMD patients increases from 26% at 10-14 
years of age to 72% at 18 years of age. At end-stages, virtually all DMD patients will 
exhibit signs of cardiac abnormalities (i.e. conduction defects, arrhythmia, dilated or 
hypertrophic cardiomyopathy) until they eventually succumb to heart failure [13]. It 
should be noted that “typical” heart failure symptoms (e.g. orthopnea, dyspnoea, or 
exercise limitations) are often absent or hidden by skeletal muscle impairment in DMD, 
causing significant delays in evaluation and treatment [6,14].  
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1.1.4 Clinical Symptoms of the Dystrophic Brain  
As DMD is a neuromuscular disorder, there are cognitive and neuropsychiatric 
implications associated with this disease. However, most literature prioritizes 
investigating the skeletal muscle degeneration associated with DMD, resulting in 
minimal knowledge on both cognitive and anatomical symptoms of the DMD brain. 
Additionally, the literature regarding the DMD brain is still heavily debated on and is 
often contradictory in nature. However, it is generally agreed upon that approximately 
20-50% of DMD patients will exhibit cognitive and behavioural issues [15]. DMD boys 
are reported to have an increased likelihood of intellectual disabilities relative to both the 
general population and to their unaffected siblings—ruling out confounding 
socioeconomic factors (e.g. familial income, parent education level, etc.) [16]. 
Quantitatively, DMD patients typically have an average intelligence quotient (IQ) of 
approximately 85, which is one standard deviation below the average population. These 
reductions remain consistent when assessing Full Scale Intelligence Quotient tests 
(FSIQ), although these patients seem to demonstrate lower verbal IQ scores (VIQ) but 
not performance (PIQ). Both IQ and FSIQ scores in patients appear to be non-progressive 
as neither were observed to correlate with age nor disease severity [17,18].  
While IQ and FSIQ are a good measure of general intelligence, it should be noted that 
DMD patients also suffer a specific pattern of cognitive and behavioural symptoms—
albeit with considerable variability between individuals. Broadly, DMD patients can 
exhibit specific impairments in phonological awareness/processing, attention, visuo-
spatial abilities, both verbal and visual working memory, and other executive functions 
(i.e. planning inhibition, set shifting, etc.) [17–19]. Cognitive impairments may manifest 
in school-aged DMD boys as limited vocabulary, poor language comprehension, 
inattention, weak working memory, and learning disabilities in reading, mathematics, and 
writing (i.e. dyslexia, dyscalculia, and dysgraphia) [20]. These deficits in cognitive 
function seem to persist during adulthood, as adult DMD patients (mean age of 30) seem 
to experience impaired attention, poor memory, and an inability to process auditory 
information [21]. DMD also shares brain-related comorbidities with the development of 
several other neurological and psychiatric disorders, such as an increased prevalence of 
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epilepsy (7.9%), autism spectrum disorders (15%), anxiety disorders, attention-deficit 
(hyperactivity) disorder (32%), and obsessive-compulsive disorders (4.8%). Interestingly, 
this is also found with transient neurological attacks [22]. For instance, in a retrospective 
review study of 59 males; patient records indicated that arterial ischemic stroke was more 
prevalent in DMD patients (occurring at an incidence of 1 per 100 patient years in 
comparison to current childhood ischemic stroke incidence of 1.6 per 100,000) [23,24]. 
At the same time, literature also indicates a high degree of inter-individual variability 
across cognitive symptoms between DMD patients. These symptoms cover a broad range 
of cognitive abilities—in which some are highly expressed, while others are nonexistent 
in particular individuals [17–19].  
Similar aspects of heterogeneity are also prevalent within the anatomical architecture of 
DMD brains. For instance, some studies have indicated morphological abnormalities, 
while others suggest no gross structural differences between the dystrophic and healthy 
patient. In general, the dystrophin-deficient brains reportedly experience neuronal 
loss/reduced brain weight, gliosis, cerebral heterotopia, increased cortical thickness, and 
various alterations to brain microstructures (i.e. aberrant dendritic development and 
arborization, altered synaptic ultrastructure, etc.) [17,25–27]. However, these features are 
inconsistent and seem to vary between individuals. For instance, upon evaluating the 
post-mortem attributes of 13 DMD patient brains, the majority displayed no difference in 
brain weight nor gross anatomical structures. Despite no major anatomical differences, 
three patients within the study demonstrated histological dendritic abnormalities and 
arborization, while another patient demonstrated severe neuronal loss, astrogliosis, 
purkinje cell loss, and cerebral heterotopia [28]. While it is still uncertain if these 
morphological abnormalities are associated with impaired cognitive function, some 
neuroimaging studies have demonstrated decreased glucose metabolism within select 
regions of the dystrophic brain—which is typically indicative of cognitive impairment 
[17]. Interestingly, some studies have also indicated possible cerebral degeneration within 
DMD patients. For instance, using computer tomography (CT), Yoshioka et al. [29] 
observed that older DMD patients displayed more severe cerebral atrophy (i.e. enlarged 
internal and external cerebrospinal fluid space, abnormal cistern and sulci evaluation) 
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than the younger patients. Despite these investigations, no correlation was found between 
IQ, age, and DMD disease severity within these patients.  
Historically cognitive symptoms appear to be non-progressive in DMD patients. 
However, recent studies have indicated that these cognitive deficits may progress, but its 
phenotype is only seen within older subsets of both DMD patients and animal models 
[21,30,31]. For instance, within a comparative executive function study using the 
Wisconsin Card Sorting Test (WCST), DMD patients (aged 30-37) had an average 
WCST score that was nearly 50% lower than their younger DMD counterparts (age 18-
25) [30]. These results were consistent within aged mdx mice (age 18 months), as they 
displayed decreased hippocampal spatial learning, impaired memory, and heightened 
anxiety-related behaviour compared to their younger counterparts (age 4 months) [31]. 
This indicates that with increasing age, DMD patients may experience delayed-onset 
neurodegeneration, possibly further hindering the quality of the later stages of their lives.  
Thus, due to the improved management of skeletal and respiratory dysfunctions, more 
patients are now surviving long enough for the emergence of heart failure and cognitive 
impairment associated with the later stages of the disease. With this increased longevity 
in DMD patients, the clinical relevance of downstream cardiac and neurodegeneration 
become abundant, increasing the need for a better understanding of both cardiac and 
neurological involvement. As such, this thesis will primarily focus on the dystrophic 
heart and brain.  
1.2 Pathophysiology 
1.2.1 Overview of Dystrophin 
The DMD gene, notably the largest gene in the human body, contains nearly 2.5 million 
DNA base pairs and 80 exons. Being tightly regulated by sets of internal promoters, it 
produces a diverse plethora of protein isoforms (called dystrophin protein variants) with 
unique functions specific to various tissues of the body (e.g. retina, skeletal and cardiac 
muscle, brain, schwann cells, etc). Examples of these dystrophin protein variants include 
full length dystrophin Dp427 (mainly expressed in skeletal and cardiac muscle), and 
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Dp140 and Dp71 (mainly expressed in the brain) [12,25,32]. Duchenne muscular 
dystrophy arises due to a mutation in any region within the DMD gene, with the most 
common being a frameshift mutation due to a deletion of one or more exons. The lack of 
functional dystrophin, within several regions of the body, can lead to various symptoms 
as this disorder simultaneously affects multiple organs—further building on DMD’s 
reputation as a systemic disease [12,33].  
1.2.2 Dystrophic Cardiac Pathology 
Dp427 is the resident dystrophin isoform within the skeletal and cardiac muscle, 
specifically located on the inner side of the sarcolemma within myocytes. It is 
hypothesized that dystrophin forms the dystrophin-associated protein complex (DAPC) 
along with other transmembrane proteins (i.e. dystroglycans, sarcoglycans, etc.), and 
serves as a link between the cytoskeletal actin filaments, contractile units of myofibers, 
and the extracellular matrix’ laminin protein (Figure 1.1). As such, dystrophin 
mechanically stabilizes the plasma membrane during contraction by transferring the 
forces generated by the sarcolemma to the extracellular matrix. In addition, dystrophin 
(and the DAPC) is also integral in enabling signal transduction between the intra- and 
extracellular environment. A notable example is neuronal nitric oxide synthase (nNOS), 
which is localized to the sarcolemma by dystrophin. This facilitates the nitric oxide (NO) 
synthesis signaling pathway and subsequently signals blood vessels dilation, allowing the 
passage of oxygen and nutrients to muscle cells [34–36].  
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Figure 1.1 Dystrophin serves as an integral component of the Dystrophin-associated 
protein complex (DAPC) and links the actin cytoskeleton to extracellular matrix 
(ECM). Schematic displays the binding of the actin cytoskeleton-bound dystrophin to 
DAPC transmembrane proteins (i.e. sarcoglycan, dystroglycans), which anchors laminin-
bound ECM. This complex serves to stabilize the sarcolemma during muscle contraction. 
Dystrophin may also interact with additional proteins (i.e. nNOS) at the sarcolemma, 
allowing for signal transduction [35].   
Within dystrophinopathies, there are many theories for the degeneration of cardiac 
muscle. Among them is the “two-hit” hypothesis model, which speculates that the 
dystrophic phenotype is not caused by one exclusive mechanism, but rather the 
cumulative effects of multiple stressors. In this model, the first “hit” is the destabilization 
of the DAPC. During DMD, the absence of dystrophin (and associated DAPC) causes the 
muscle cells to be vulnerable to mechanical stress, increasing the susceptibility of the 
cells to damage during cardiac muscle contractions. As a result, contractile forces cause 
the shearing and tearing of the sarcolemma membrane [4,34,37]. Immune cells (i.e. 
neutrophils, mast cells, and macrophages) are recruited to the sites of mechanical damage 
to help with phagocytosis of cell debris and to release inflammatory cytokines that can 
instigate myonecrosis [5,38]. Additionally, the myocyte’s tearing can increase membrane 
permeability, causing an abnormal influx of calcium ions from the extracellular space 
into the cell. Furthermore, this dysfunctional calcium influx may be a result of 
impairments to the L-type calcium channels and mechanical stretch-activated receptors—
which regulates the depolarization and contraction of the cardiomyocyte via calcium ions. 
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This intracellular calcium causes further problems as it can activate proteases (e.g. 
calpain), which are thought to degrade a wide variety of contractile proteins and induce 
myocyte necrosis [36,38,39].  
The second “hit” is often described as damage that is environmentally or indirectly 
induced [12]. For instance, the excess calcium levels within myocytes were also found to 
trigger the release of reactive oxygen species (ROS). In cardiac muscle, ROS promotes 
inflammatory cell recruitment by activating inflammatory signaling pathways (i.e. NF-
kB) and releasing pro-inflammatory cytokines [38,41–43]. These immune cells (e.g. M1-
like and M2-like macrophages, neutrophils, T-cells, etc.) are recruited and typically 
found at the site of cardiac injury [44]. In particular, pro-inflammatory macrophages are 
thought to attack cardiac myofibers and exacerbate the myonecrosis process upon chronic 
activation, further damaging the sarcolemma [5,38,45]. Additionally, ROS can trap these 
macrophages at the site of inflammation by upregulating cytokine macrophage migration 
inhibitory factor—prolonging the damage [46]. During this myonecrosis process, these 
inflammatory macrophages can also release pro-inflammatory cytokines, which may 
trigger fibroblasts to produce collagen in the extracellular matrix. Increased collagen 
deposition is notably dangerous, as it leads to fibrosis—particularly in regions of high 
contractility and movement (e.g. left ventricle). As a result, elastic cardiac muscle is 
replaced with segments of rigid fibrotic tissue, which can cause pre-clinical symptoms of 
cardiomyopathy such as conduction defects or decreased systolic ejection [38,39,44].  
Ischemic injury, caused by the mislocalization of neuronal nitric oxide synthase (nNOS), 
can also contribute to acute myocyte death. nNOS is normally bound to the sarcolemma 
by the DAPC. Thus, with dystrophin’s absence, nNOS is unanchored and will localize to 
the cytosol. This process causes vasoconstriction of the blood vessel—leading to 
inadequate blood flow, poor oxygen regulation, and ultimately muscle ischemia. The 
rapid accumulation of inflammatory cells to the site of ischemic injury may also lead to 
the induction of myonecrosis [47–49].   
In summary, current literature dictates that the DMD cardiac phenotype is the product of 
several complex and multi-faceted cascades arising from the dystrophin protein 
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dysfunction. While mechanical injury and membrane defects are thought to be the initial 
causes of DMD, secondary mechanisms encompassing chronic inflammation, fibrosis, 
and ischemia also seem to contribute to this defective pathophysiology. Thus, a better 
understanding and tracking of these secondary mechanisms—specifically 
inflammation—may lead to a better understanding of cardiac outcomes.  
1.2.3 Dystrophic Neural Pathology  
Unlike the full-length dystrophin (Dp427) found in cardiac and skeletal muscle, 
dystrophin within the brain are expressed as several protein isoforms of varying lengths. 
Different isoforms (e.g. Dp427, Dp140, and Dp71) are localized to specific brain 
regions/cells and participate in various cellular functions. For instance, Dp427 typically 
localizes to the neurons in the cerebellum, cortex, and hippocampus, while Dp71 
typically localizes to astrocytes and glial cells [25,32,50]. While the etiology behind 
DMD patients’ cognitive symptoms remain unknown, it is suspected to be caused by a 
mutation to certain regions of the DMD gene leading to the loss of one or more 
dystrophin protein isoforms [25]. For instance, in a large genetic study containing 65 
DMD patients, the risk of cognitive deficit—portrayed by FSIQ scores—is highly 
correlated to gene location and the resultant types of isoforms lost. Here, patients who 
had lost the shorter isoforms (i.e. Dp71) yielded the lowest FSIQ compared to those who 
lost only the longer isoforms (i.e. full-length Dp427) [51]. As such, the heterogeneity of 
DMD cognitive dysfunction is thought to be caused by the cumulative loss of different 
dystrophin isoforms.      
Unfortunately, the exact function of each dystrophin protein variant within the brain is 
still vastly uncharacterized. Within murine models, Dp427 has been found to colocalize 
with a subset of γ-aminobutyric acid (GABAA)—a neurotransmitter important for the 
regulation of learning and memory— receptors clusters within the synaptic regions of the 
cerebellum, cerebral cortex, and hippocampus [50,52,53]. Alike to muscle cells, Dp427 is 
suspected to be integral to the formation of DAPC-like structures within the brain, which 
may aid in the stabilization/anchoring of GABAA receptors to the neuronal post-synaptic 
membranes [54]. In support of this, mdx mice were observed to have a notable reduction 
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in the number of GABAA receptor clusters in the cerebellum [53]. As such, Dp427 may 
play a role in maintaining GABAergic synaptic function. The loss of Dp427 may alter 
signal transduction/synaptic plasticity, leading to learning/memory deficits seen in DMD 
patients [54,55].  
Despite being the most abundant dystrophin protein variant in the adult brain, Dp71 
typically localizes to perivascular end-feet of astrocytes and clusters of water channel 
protein aquaporin-4 (AQP4) receptors [32,56]. Both of these structures are important in 
maintaining the blood-brain barrier (BBB). Astrocytes’ end-feet processes interact with 
endothelial cells and pericytes form tight junctions to restrict the entry of non-specific 
molecules from circulation into the brain. On the other hand, AQP4 channels control 
water influx into the brain. Thus, it is suspected that Dp71 may contribute to the 
modulation of BBB permeability [32,57,58]. While the exact role of dystrophin protein 
within the BBB has yet to be confirmed, several investigators have demonstrated its 
importance in maintaining BBB function/vascular permeability through several DMD 
murine studies. For instance, Nico et al. [58] observed that the BBB of mdx adult mice—
a murine model of DMD—suffered severe damage and subsequently disrupted. Most 
notably, the authors histologically observed increased vascular permeability, less 
endothelial tight junction protein expression, decreased AQP4 protein, and the emergence 
of swollen and degenerating perivascular end-feet, marked by a discontinuous 
envelopment of endothelial vessels. Similar incidences of disrupted BBB integrity and 
cerebral diffusivity were confirmed to occur in-vivo in mdx mice [59]. To the best of my 
knowledge, the correlation between BBB disruption and cognitive impairment within 
DMD has yet to be studied. However, it is common for BBB breakdown to initiate 
cognitive impairment within several other neurodegenerative diseases (e.g. Alzheimer’s 
dementia, Parkinson’s disease, and multiple sclerosis) [60]. Interestingly, an altered BBB 
integrity coupled with increased neuroinflammatory infiltration is thought to contribute to 
the increased risk of Autism spectrum disorder and epilepsy—both common 
comorbidities in DMD patients [61,62]. As such, it is possible that the altered BBB 
permeability seen in DMD mice is also associated with neuroinflammation, which in turn 
can contribute to the emergence of DMD cognitive impairment and neurodegenerative 
symptoms.  
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Although chronic inflammation is a key component of DMD muscle pathophysiology, 
only recently has there been increasing consideration of neuroinflammation’s 
contribution to cognitive impairment within this disease [54,63]. In a recent study, mdx 
mice who exhibited DMD-like cognitive symptoms (i.e. impaired memory, depression- 
and anxiety-like behaviour) also had elevations of pro-inflammatory cytokines (i.e. IL-1β 
and TNFα) and increased MPO activity (an analog for inflammation and leukocyte 
infiltration) in their brains [64]. In support of this, two speculative reviews propose that 
these pro-inflammatory cytokines are likely to disrupt hippocampal function in 
dystrophinopathies, which facilitates learning/memory processing. For example, the 
upregulation of IL-1β is speculated to modify GABAergic synaptic transmission by 
altering the expression of inhibitory hippocampal GABAA receptors—features that are 
typically observed in mdx mice. Although the mechanisms underlying these 
inflammation-induced memory deficits are not well-understood, it is proposed that such 
alterations may result in the increased potentiation of GABAergic inhibitory currents, 
which is associated with memory deficits [54,63]. Thus, although the current literature 
outlining inflammation’s role in dystrophic neuropathy are few and speculative in nature, 
these findings highlight the potential role of immune molecules in modulating neurologic 
function within the dystrophic brain.  
1.3 Inflammation Contributes to DMD Cardiac and 
Neurologic Outcomes  
While dystrophin-absent mechanical injury and membrane defects are thought to be 
proximate causes of DMD, secondary mechanisms (such as chronic inflammation, 
fibrosis, and ischemia) also contribute to the defective pathophysiology [5]. As 
previously discussed in 1.2.1, chronic inflammation is an imperative component in DMD 
cardiac muscle pathogenesis—as sarcolemma damage causes the recruitment of activated 
glial cells and the secretion of pro-inflammatory cytokines. Due to the multitude of 
signaling pathways and its participants, the mechanism to how inflammation affects 
DMD muscle pathophysiology is highly complex. While the mechanism underlying how 
each individual participant (e.g. neutrophils, M1-like and M2-like macrophages, 
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inflammatory cytokines, etc.) affects dystrophic muscle remains unclear, they all 
cumulatively contribute to the development of cardiomyopathy and possibly the eventual 
emergence of heart failure [5]. In particular, macrophages are thought to have a central 
role in exacerbating dystrophic muscle damage—since an abundance of macrophages and 
neutrophils were shown to localize to regions of cardiac necrosis/lesions in 
immunohistochemical staining of dystrophic mice hearts [45]. In addition, mdx models 
with a predisposition for inflammation demonstrated extensive M1-like macrophage 
infiltration and more severe cardiorespiratory dysfunction (i.e. decreased fractional 
shortening and ejection fraction) compared to normal mdx models [38]. After removing 
the macrophages from the muscle prior to the onset of myocyte necrosis (3-4 weeks), 
mdx mice will later have a 70-80% decrease in number of injured muscle fibers (~3 
months of age) [65]. These findings further demonstrate the importance of inflammation 
in dystrophic cardiac outcome, emphasizing the need to better assess its presence in 
DMD models as its attenuation may aid in slowing down cardiac dysfunction.  
Similarly, neuroinflammation—depicted as heightened pro-inflammatory cytokines—in 
the dystrophic brain is increasingly considered to be a contributor of cognitive 
impairment associated with this disorder [54,63]. While much about this hypothesis 
remain unclear, activated microglia—which commonly acts as the source and target of 
these inflammatory cytokines—are implicit in the development of several other 
neuroinflammatory and degenerative diseases, such as: Alzheimer’s dementia (AD), 
Parkinson’s disease, and frontotemporal dementia [66]. Interestingly, activated microglia 
have also emerged as a prime component of late-onset AD, in which similar to DMD, the 
clinical symptoms of cognitive degeneration do not emerge until the later stages of life 
[67]. To the best of my knowledge, no study thus far has demonstrated the presence of 
activated microglia within the dystrophic brain. However, with this information and a 
better understanding of neuroinflammation in DMD, there is the potential to develop anti-
inflammatory neuroprotective therapies that may improve patient’s cognitive function at 
the later stages of this disease.  
Due to the potential consequences of unchecked inflammation on the heart and brain, 
there is a need to better understand the role of inflammation in multi-organ 
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degeneration—as it may lead to the subsequent development of effective therapeutic 
strategies that targets multiple bodily systems, especially brain and heart resilience in 
DMD patients. However, a valid assessment tool must be developed in order to track 
inflammatory status within several organs—especially in the heart and brain of DMD 
patients.  
1.4   Assessments of Inflammation  
As previously discussed in section 1.3, inflammation holds a great deal of importance as 
not only a localized response to tissue/organ injury, but also as a potential contributor to 
downstream cardiac and neurological outcomes. As such, the assessment of inflammatory 
response within DMD could aid in tracking disease progression and in developing 
effective therapeutic strategies targeted to before the onset of severe cardiac or 
neurological damage. Currently inflammation is not routinely monitored during clinical 
DMD progression assessments. However, in other diseases, inflammatory load can be 
assessed ex-vivo using in-fluid circulating inflammatory markers (i.e. C-reactive protein, 
IL-6, etc.) and histopathological trafficking of immune cells, or in-vivo via non-invasive 
molecular imaging [68]. Similar applications can foreseeably be done in DMD.  
1.4.1 Ex-vivo Assessments 
It is well-established in literature that inflammation can be assessed through several 
different methods, ranging from: the novel inflammation-on-a-chip devices (an ex-vivo 
contraption that uses microfluidic tools to visualize cellular events in a controlled tissue 
microenvironment) to the more traditional and clinically-used biomarkers such as:  
inflammatory cytokines (e.g. IL-6, TNF-α, IL-1β) and acute phase proteins (e.g. C-
reactive protein) [68,69]. Cytokines are secreted by immune cells (i.e. activated 
macrophages and monocytes) at the site of inflammatory injury. However, they are also 
found within circulation as they are crucial mediators of both local and systemic 
reactions, allowing them to be contributors to the aetiology of chronic diseases [70]. 
Similarly, C-reactive protein (CRP) exhibit elevated expression during inflammatory 
conditions in cardiovascular and cerebrovascular diseases [71,72]. These molecules can 
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be significantly upregulated in response to tissue-induced inflammatory activity within 24 
to 48 hours after initial insult [73]. These circulating inflammatory markers can be 
measured ex-vivo by analyzing plasma/serum from blood or from other invasive locations 
(e.g. saliva, urine, and cerebrospinal fluid). The use of in-fluid biomarkers is 
advantageous because they are simple, fast to conduct, and are able to evaluate an 
inflammatory or infectious state [74]. However, inter-individual genetic variations can 
specifically increase plasma CRP levels regardless of inflammatory status, limiting its 
sensitivity and specificity [73,74]. In addition, it does not identify the source nor target of 
the inflammatory response, leaving little information on which organ(s) are damaged. As 
such, despite in-fluid biomarkers’ ability to assess inflammatory status, it is limited in its 
identification of the inflammatory location. 
On the other hand, tissue-specific inflammatory information in the heart and brain can be 
acquired ex-vivo with endomyocardial and brain biopsies. The removed segments of 
neural and cardiac tissue are often histologically stained and microscopically examined, 
allowing us to visualize and assess the extent and exact location of the inflammatory 
infiltrate with a high degree of specificity [75,76]. However due to its invasive nature, the 
amount of tissue obtained is minimal and thus, may not be representative of the whole 
organ’s pathological status [77]. In addition, the localized nature of invasive tissue 
biopsies is a concern within DMD assessment since DMD is a whole-body systemic 
disease. This limitation can be extended to most ex-vivo vectors. As such, tissue biopsies 
may be insufficient in observing inflammatory load within multiple organs 
simultaneously without extensive surgical procedure, and the information obtained may 
not even be indicative of that organ’s pathological state. 
1.4.2 In-vivo Assessments 
In-vivo imaging technology is understandably better suited than ex-vivo technology in 
observing the overall inflammatory effects on a living subject in real time. In regard to 
inflammatory imaging, there are a few alternatives that can be considered. For instance, 
magnetic resonance imaging (MRI) has been used to evaluate the pathogenesis of several 
inflammatory disorders and to study cardiac involvement in DMD patients [78,79]. This 
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imaging modality uses an external magnetic field to first align the typically randomly-
oriented hydrogen within water molecules in the subject. Various external radiofrequency 
(RF) energies—also known as RF pulse sequences—are applied, resulting in the 
excitation of the aligned proton atoms. Upon their relaxation from this excited state, the 
proton will emit signals that are detected and recorded both temporally and spatially by 
the scanner. These signals are then transformed, resulting in a high-quality anatomically 
and structurally accurate image. Depending on the RF pulse sequence applied and the 
detected relaxation time of the excited proton (known as T1- and T2- relaxation times), 
different functional information can be inferred. Conventionally T2 relaxation times are 
increased in tissue lesions or regions of edema (often associated with elevated 
inflammation)—resulting in these regions appearing brighter than surrounding normal 
tissue in MR images [79]. As a result, T2-relaxation time mapping is used to determine 
the pathologic state of the affected tissue, while allowing us to identify the organ of 
damage/region of inflammatory infiltration within the affected subject. In contrast to ex-
vivo assessment tools, MRI can not only identify abnormal pathophysiology in tissue-
specific regions, but can also image the entire body—allowing us to acquire information 
regarding multiple organs simultaneously in one scan. While T2-weighted imaging has 
been successful in differentiating between the muscle of DMD and healthy patients, its 
specificity as a marker of inflammation is limited due to the confounding influence of 
edema or fat infiltration [80,81]. In addition, inflammatory foci are virtually undetectable 
in the earlier stages of disease progression if no blatant anatomical changes are present. 
In summary, T2-weighted MRI may be a useful tool for the body-wide assessment of 
DMD, but it is limited by its specificity and sensitivity in detecting inflammation.  
Another imaging modality is positron emission tomography (PET). PET is a non-invasive 
imaging technique that relies on the in-vivo detection of a radioactive tracer—also known 
as a radiotracer—as it binds specifically to a region/receptor of interest. A radiotracer, by 
definition, is the radioactive element-labelled (e.g. 18F, 11C, or 15O) ligand or substrate 
that are highly specific for that targeted enzyme or receptor within the body. It is due to 
this ligand-binding specificity that gives PET its identity as a molecular imaging 
modality, as it can visualize and measure these biological processes at molecular and 
cellular levels [82]. As such, PET offers higher sensitivity as it can detect imaging agents 
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at a 10-11-10-12 molar level in contrast to MRI (at approximately 10-3-10-5 molar) and CT 
(at approximately 10-2-10-3 molar) [83]. To conduct PET imaging, a tracer is administered 
(usually by injection or inhalation). Depending on the positron-emitting radioisotope 
bound to the tracer, a specific percentage of the nuclei will decay by emitting positrons. 
These positrons generally travel a certain distance before colliding or annihilating with an 
electron, resulting in the production of two 511keV photons that are expelled at a 180° 
angle. Using opposing detectors within the scanner, the detection of these expelled 
photons in coincidence allows for the localisation of the source of this emission (i.e. the 
tracer) and tracer activity concentration within the subject. Thus, alike to MRI, this 
imaging modality allows us to identify regions of affected pathophysiology 
simultaneously in multiple organs in real time from a single scan. However, unlike MRI, 
PET can identify the presence of inflammation at a much higher specificity depending on 
the radiotracer of choice. To the best of my knowledge, there has yet to be a study 
conducted with the goal of imaging inflammation in DMD using PET. However, this 
imaging modality may be useful in assessing inflammatory status in-vivo as it has already 
successfully demonstrated its utility in several other inflammatory disorders (e.g. cardiac 
sarcoidosis, vasculitis, and rheumatoid arthritis) [84].  
1.5 Inflammatory PET Radiotracers 
1.5.1 Glucose-metabolism Analogue Tracer – FDG 
The most extensively used radiotracer within both the research and clinical environment 
is 2-deoxy-2-18F-fluoro-D-glucose (18F-FDG), a glucose analogue that allows for the 
quantification of glucose metabolism within metabolically active cells/tissues. While not 
a direct marker of inflammation, it has shown significant value for successful imaging of 
cardiac and neural inflammatory diseases, such as atherosclerosis, vasculitis, Alzheimer’s 
dementia, and multiple sclerosis [85,86]. This can be attributed to the fact that immune 
cells—in particular macrophages/microglia and neutrophils—have an increased demand 
for glucose than peripheral non-inflammatory cells. As such, sites of significant 
[18F]FDG uptake can be used to identify regions of activated macrophage accumulation 
[83,87]. However, the imaging of inflammation with [18F]FDG PET has the tendency to 
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yield false-positive results (e.g. accumulating in metabolically active benign tumors or 
brown adipose tissue) [88,89]. In addition, the heart and brain are naturally very 
metabolically-active organs. As a result, there is a higher level of tracer accumulation 
within those areas, making it difficult to detect inflammatory infiltrates in those areas 
without it being obscured by background activity [83,88]. Thus, there has been increasing 
reliance on more specific inflammatory radiotracers that target macrophage or microglia 
directly. 
1.5.2 Translocator Protein (TSPO) Tracer – FEPPA 
One candidate that has been increasingly used to image inflammation are radiotracers that 
bind to translocator protein (TSPO). Also known as peripheral benzodiazepine receptor 
(PBR), TSPO is a 18kDa transmembrane protein located on the outer membrane of 
mitochondria, and is constitutively expressed at low-to-moderate levels in several organs 
(e.g. kidneys, adrenal glands, lungs, and the healthy myocardium and brain parenchyma) 
[90]. Specifically, within the healthy brain, TSPO is also expressed at minimal amounts 
on resting microglial cells [91]. However, during cases of neurological disease/injury and 
inflammation, TSPO is considerably upregulated specifically on activated microglia and 
reactive astrocytes [92,93]. In fact, several studies have indicated a colocalization of 
TSPO overexpression and activated microglia in both acute injury and chronic 
degenerative disorders—including multiple sclerosis, Parkinson’s and Alzheimer’s 
dementia [92,94]. For instance, audioradiograms and confocal microscopy demonstrated 
that sites of TSPO-tracer binding overlapped with regions rich in CD68-stained activated 
macrophages and microglia nodules in brain sections of macaques suffering from simian 
immunodeficiency virus encephalitis [95]. As such, TSPO-PET is highly used in research 
for the detection of regions particularly abundant in microglia activation, which are 
typically regions associated with neuronal damage.  
Recently, TSPO-PET radiotracers have been increasingly used outside of the neural 
environment to image inflammation in peripheral organ diseases. Despite its ubiquitous 
expression in several tissues, several studies have demonstrated significantly higher 
levels of TSPO expression in peripheral organs during disease-induced inflammation than 
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that of healthy controls [91,96]. For instance, the myocardium of experimental 
autoimmune myocarditis models demonstrated an approximate 3.7-fold higher level of 
TSPO expression than that of healthy controls. These areas of increased TSPO expression 
were also colocalized immunohistochemically with regions highly concentrated with 
CD68+ macrophages [97]. Likewise, autoradiography and immunohistostaining of a 
murine CD68+ carotid, and fibrotic human carotid tissue samples indicated TSPO-tracer 
localization within inflamed and damaged areas [98,99]. Furthermore, [11C]PK11195—
another TSPO radiotracer—has been successfully used to image both cardiac and 
neuroinflammation within a patient post-myocardial infarction, demonstrating TSPO-
PET’s feasibility as a multi-organ inflammation-investigative tool [94]. Thus, the PET 
imaging of TSPO in both activated macrophages and microglial cells, may be sensitive 
enough for the in-vivo detection and quantification of inflammation body-wide within 
DMD.  
Currently there are several TSPO-associated radiotracers used in literature that have 
successfully imaged both cardiac and neuroinflammation across several diseases [91,96]. 
Examples of these include: the historic [11C]-(R)-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)-3-isoquinoline-carboxamide ([11C]PK11195), and the second generation 
tracer [18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide 
([18F]FEPPA) [100,101]. [11C]PK1195 is the most widely studied and has vastly 
contributed to delineating the role of inflammation in several acute and degenerative 
disorders [102,103]. However, there is an increasing reliance on second generation TSPO 
radiotracers (e.g. [18F]FEPPA) as they resolve some of the challenges associated with 
[11C]PK1195—such as short half-life of 11C, better brain penetration, and increased 
specificity [104,105] . Having been radiolabeled with 18F, these TSPO radiotracers have a 
longer half-life of 109.8 minutes, allowing for more extensive research with relatively 
less temporal restriction. In addition, [18F]FEPPA has comparatively better binding 
potential, specificity, and penetrative ability of the BBB than [11C]PK1195—thereby 
being a better in vivo assessment tool for  inflammation in both the dystrophic heart and 
brain [106].  
19 
 
1.6 Pre-clinical Murine Models of DMD  
There is an abundance of animal models for DMD, ranging from small non-mammalian 
Drosophila melanogaster to larger newly developed pig models. However, rodent models 
remain one of the most widely used vectors due to their genotypic and pathological 
resemblance to DMD-diagnosed humans. Amongst the many strains is the mdx mouse, 
which has no functional dystrophin protein due to a point mutation in the X-chromosome 
of the DMD gene so that like its human counterpart, will possess no functional dystrophin 
protein [107]. As a result, this murine model can demonstrate histopathological 
characteristics of tissue degeneration and inflammatory infiltrate within skeletal muscle 
[108]. In addition, mdx mice also exhibited signs of cognitive dysfunction in the form of 
impaired visuospatial memory, impaired avoidance memory, anxiety, and depressive 
behaviours within 8 weeks of age [64,109,110]. In addition, they are known to exhibit a 
reduced capacity to learn and store spatial memories [109,111]. However, this strain’s 
efficacy is greatly decreased as they exhibit none or mild non-progressive 
cardiomyopathy even after 10 months of age—despite showing a degree of inflammation, 
cellular necrosis, and fibrosis within their myocardium [112]. This can be attributed to 
the compensatory effects of dystrophin protein homolog, utrophin. Unlike their human 
counterparts, utrophin in mdx mice can substituted structurally for dystrophin within 
muscle—restoring DAPC and subsequently leading to an improved muscle pathology 
[113].  
On the other hand, the mdx:utrn(+/-) mouse is able to exhibit a slightly more severe 
phenotype as it only possesses one functional copy of the utrophin protein. For instance, 
both skeletal and cardiac muscle of mdx:utrn(+/-) models exhibit more severe collagen 
deposition and fibrosis than that of mdx mice [114]. As such, it is often referred to in 
literature as a more accurate model of DMD phenotypically. To the best of my 
knowledge, the cognitive impact within the mdx:utrn(+/-) model has yet to be 
characterized.  However, as these models depict a more severe phenotype, they are 
predicted to show greater cognitive impairment than within the mdx model.  
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1.7 Research Outline  
Within this thesis, mdx:utrn(+/-) mice were utilized. Specifically, 8-10 week old murine 
models were selected, as evidence of cognitive impairment and early signs of cardiac 
fibrosis (but not cardiomyopathy symptoms) have been reported at this age [64,115]. This 
age group may provide information about inflammation prior to severe tissue damage. 
After an injection with [18F]FEPPA, PET images were taken of the whole body to better 
assess inflammatory load collectively on a multi-organ level. In order to validate the 
[18F]FEPPA PET data and quantify TSPO-tracer ex-vivo, autoradiography and 
biodistribution were conducted on not only the heart and brain but also several peripheral 
organs. Autoradiography was conducted on the thoracic and abdominal aorta, heart, 
brain, gastrocnemius, soleus, extensor digitorum longus, tibialis anterior, and liver. In 
addition to these tissues, biodistribution was also conducted on the large intestine, small 
intestine, diaphragm, tibia/fibula, tail, pancreas, lungs, and spleen. These data provide a 
better understanding of inflammation on a systemic level. Immunohistochemical staining 
with anti-TSPO antibody was also examined to further validate if the TSPO-tracer is 
localizing to the cardiac and neural tissue.  
1.7.1 Study Objectives 
1. To develop a non-invasive imaging protocol to assess in vivo inflammatory 
involvement in DMD simultaneously in several organs using [18F]FEPPA PET 
2.  To investigate the role of inflammation in the heart and brain of DMD murine 
models 
1.7.2 Study Hypothesis  
We hypothesized that subjects with DMD demonstrated heightened levels of 
inflammation in dystrophic cardiac and neural tissues.  
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Chapter 2  
2 In-vivo imaging of cardiac and neuroinflammation in 
Duchenne muscular dystrophy mice: a [18F]FEPPA PET 
study 
This chapter has been adapted from the following manuscript:  
Tang JM, McClennan A, Liu L, Hadway J, Ronald J, Hicks JW, Hoffman L, Anazodo 
UC. In-vivo imaging of cardiac and neuroinflammation in Duchenne muscular dystrophy: 
a [18F]FEPPA PET study. Submitted to Neuromuscul Disord in August 2020. Under 
Review. Manuscript ID: NWD-S-20-00539. 
2.1 Introduction 
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular degenerative 
disease, affecting approximately 1 in 3600 live male births worldwide. Individuals with 
DMD are unable to produce functional Dystrophin protein which is found systemically 
across various tissues, notably in skeletal and cardiac muscle, and neurons in the central 
nervous system (CNS). As a result, DMD is clinically characterized by progressive 
skeletal and cardiac muscle degeneration along with cognitive impairment [1–3]. These 
multi-organ degenerations are exacerbated by fibrosis, ischemia, and chronic 
inflammation until an early death from cardiac or respiratory complications [4–6]. 
Although there is still no cure for DMD, recent advancements in experimental therapies 
have prolonged both ambulation and life expectancy, as fatalities previously expected by 
age 15–20, are now often observed at approximately age 30-40 [5,7].  
Due to the improved management of skeletal and respiratory dysfunctions, more patients 
are now surviving long enough for the emergence of heart failure and cognitive 
impairment associated with the later stages of the disease. In fact, more than 90% of 
DMD patients over the age of 18 show signs of cardiac involvement, with nearly 60% of 
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DMD patients dying from cardiac complications by age 19 [8,9]. Likewise 20–50% of 
males demonstrate some form of cognitive weakness which remain, and in some cases, 
exacerbates as they get older (~age 30) [10–12]. Thus, with increased longevity in DMD 
patients, the clinical relevance of heart disease and cognitive impairment in DMD is 
becoming more apparent, increasing the need for the better understanding of both 
dystrophic cardiac and neurological involvement. Currently, it is known that the 
dystrophin loss in cardiac muscles leads to membrane integrity deterioration of striated 
cardiac muscle fibers and impaired regulation of intracellular calcium levels. As with 
skeletal muscle, it is suspected that this membrane instability and associated intracellular 
calcium influx initiate the pathological cycle of chronic inflammation, fibrosis, necrosis, 
leading to damage in regions of high contractility and movement (e.g. left ventricle). The 
loss of viable myocardium leads to further fibrosis, and the clinical emergence of 
cardiomyopathy and eventually heart failure [5,6,13–15]. 
The brain is a far less studied organ in DMD, but dystrophin also plays a role in brain 
development and aging. The lack of intrinsic dystrophin gene products within CNS—
namely Dp427, Dp140, and Dp71—are thought to contribute to cognitive weakness by 
contributing to a series of functional and morphological abnormalities within the 
dystrophic brain [2,3,16]. However, the underlying mechanisms are not well understood. 
Cognitive and behavioural symptoms usually manifest in the form of lowered intelligence 
quotient (IQ) scores, learning difficulties, memory deficits, and higher incidences of 
neuropsychiatric disorders [16]. Recent investigations also report the delayed emergence 
of cerebral infarcts and progressive cognitive decline within older DMD subjects, leading 
to the possible paradigm of neurodegeneration in the later stages of disease progression 
[10,12,17].  
While mechanical injury and membrane defects are thought to be proximate causes of 
DMD, secondary mechanisms encompassing chronic inflammation, fibrosis, and 
ischemia also contribute to the defective physiology. Indeed, inflammatory cell 
infiltration is strongly associated with DMD as it is thought to exacerbate symptoms and 
promote muscular degeneration [4,6,14]. We recently demonstrated that the degree of 
inflammatory cell infiltration is correlated with disease progression within DMD murine 
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models [18]. While there is growing evidence that inflammation may be an inciting factor 
in skeletal muscle degeneration and the development of cardiomyopathy in DMD, the 
role of inflammation within the dystrophic brain in DMD is relatively unexplored—
despite neuroinflammation being a prime proponent to several pediatric and adult 
neurodegenerative disorders [4,19–21]. To the best of our knowledge, immune cell 
infiltration has yet to be demonstrated within neither the DMD patient nor animal model 
brain. However, in brain tissue from the mdx murine model of DMD, heightened levels of 
pro-inflammatory cytokines in interleukin (IL)-1β and Tumor Necrosis Factor (TNF)-α 
were found and several cognitive deficits were observed [22]. Other neurological diseases 
are also associated with increased levels of TNF-α and IL-1β [23]. Thus, considering the 
well-known consequences of unchecked inflammation potentially leading to cardiac and 
neurodegeneration, there is an unmet need to better understand the role of inflammation 
in multi-organ degeneration, as it may lead to the subsequent development of effective 
therapeutic strategies that targets multiple tissues systems especially brain and heart 
resilience in DMD patients. 
Recent advancements in non-invasive molecular imaging techniques for assessing 
inflammatory load have already inspired interest in understanding the role of 
inflammation in multi-organ degeneration in several disease systems. In particular, 
Thackeray et al. [24] demonstrated evidence of concomitant inflammation in both the 
hearts and brains of ischemic heart disease mice and patients using positron emission 
tomography (PET) imaging targeting mitochondrial translocator protein (TSPO). TSPOs 
are highly expressed on activated microglia and macrophages [25]. Thus, this exploratory 
study sought to explore the capacity of TSPO-PET imaging in assessing in-vivo 
inflammatory involvement in DMD in the heart and brain as well as across several 
organs. Specifically, we used [18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-
3-yl)acetamide ([18F]FEPPA), a second-generation TSPO tracer, to assess cardiac and 
neural inflammation in DMD [25]. We hypothesized that mice with DMD will have 
increased inflammation levels in dystrophic cardiac and neural tissues, exhibited as 
heightened TSPO-PET signal and correlative histological TSPO expression. 
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2.2 Materials and Methods 
The study was conducted at Lawson Health Research Institute at St. Joseph’s Health Care 
in London, Ontario. All animal protocols were approved by the Animal Use 
Subcommittee at Western University and were conducted in accordance with guidelines 
set by the Canadian Council on Animal Care (CCAC).  
2.2.1 Study Population 
Breeding pairs of wild-type (C57BL/10) and functional dystrophin-deficient 
mdx:utrn(+/-) (a point mutation in dystrophin gene) mice were purchased from Charles 
River and Jackson Laboratories (Bar Harbor, ME) [26]. Colonies were maintained under 
controlled conditions (19-23˚C, 12-hour light/dark cycles), and were allowed water and 
food ad libitum. Two separate groups of eight to ten week old mice were used in this 
study where the in-vivo imaging (n=4-6 mice/genotype) and ex-vivo histology cohorts 
(n=3 mice/genotype) are henceforth to be referred to as the PET and 
immunohistochemistry (IHC) cohort, respectively.   
2.2.2 Small animal PET Imaging Protocol 
All PET mice were induced in a chamber with 3% oxygen-balanced isoflurane mixture 
and then anesthetized with 1.5 – 2%; both mixtures were delivered at a constant rate of 
1L/min via a nose cone. After induction, these mice were imaged using a micro-PET 
scanner (eXplore VISTA, GE Healthcare; Inveon DPET, Siemens). To assess whole-
body inflammation accumulation, TSPO-targeted PET images were obtained after 
[18F]FEPPA tracer injection. 30 seconds following the start of the scan, a dose of 
approximately 20 MBq of prepared [18F]FEPPA in saline (approximately 5μg/kg) was 
administered via tail vein catheter for dynamic acquisition. Summarily, a 60-minute 
whole-body dynamic scan in list-mode was acquired using the Inveon system. Upon 
using the eXplore VISTA scanner, list-mode acquisition was also conducted upon a 60 
minute dynamic scan of the head-to-chest region, followed by a 30 minute full-body 
static scan. Injected dose did not exceed 0.3 mL to ensure proper animal health 
conditions. 
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2.2.3 PET Imaging Analysis 
For each subject, the dynamic PET list mode data were reconstructed into the following 
time frames: 12 × 10 s, 6 × 30 s, 5 × 60 s, 5 × 120 s, 8  × 300 s using ordered subset 
expectation maximization (OSEM) algorithm with no scatter and attenuation correction. 
Data were corrected to injected dose and decay corrected to start of PET scan using in-
house MATLAB v2019a scripts (Mathworks, Natick, MA, USA). Standardized Uptake 
Values (SUV) were generated from PET data 30-60 minutes post-injection in PMOD 3.9 
(PMOD Technologies, Zurich, Switzerland). Using manually drawn regions of interest 
(ROI), mean SUV were calculated for the left ventricle, lung, and whole brain covering 
3-4 slices. Left ventricle-to-heart ratio—used to offset lung [18F]FEPPA activity and act 
as a correlative of cardiac events—was calculated from mean SUV within each animal 
[27]. 
2.2.4 Biodistribution and Autoradiography  
The mice were sacrificed immediately after imaging through 5% oxygen-balanced 
isoflurane gas euthanasia followed by cervical dislocation. To preserve tissue anatomy, 
the mice underwent whole animal perfusion fixation via an intracardiac infusion of 4% 
paraformaldehyde (Sigma-Aldrich), and then phosphate-buffered saline (PBS) as directed 
in Gage et al. [28]. The heart and brain were dissected from the subjects. Each heart was 
bisected twice—once transversely and once along the septum—and each brain were 
bisected along the central sulcus to ensure that exactly half of each tissue was fixed in 
10% Formalin or frozen in Optimal Cutting Temperature solution (VWR) for 
biodistribution and autoradiography use respectively. Biodistribution was conducted for 
the heart, brain, thoracic aorta, diaphragm, gastrocnemius, soleus, tibialis anterior, 
large/small intestines, tibia/fibula, kidney, liver, and lungs; each organ was weighed for 
quantitative estimation of gamma counts from the 18F conjugate using the ORETC 
DSPEC50 Spectrometer. Radioactivity obtained from different organs was calculated as 
the percentage of the injected dose per gram of the tissue (%ID/g) and decay corrected to 
time of injection. Radioactivity was standardized to the dose injected into each animal. 
For autoradiography, frozen tissue samples were cryosectioned into a thickness of 20 μm 
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with a Leica Clinical Cryostat (CM1850, Leica Biosystems, Wetzlar, Germany). 
Autoradiographic images of the heart, brain, thoracic aorta, diaphragm, gastrocnemius, 
tibialis anterior, kidney and liver were acquired for 12 h using a digital autoradiography 
system (JTV-18-0008, AI4R, Nantes, France) fitted with a HEEL positron holder.   
2.2.5 Histology  
2.2.5.1  Tissue Preparation  
To supplement data from acute imaging for immunohistochemistry analysis, a cohort of 
mice were sacrificed through cervical dislocation following CO2 gas euthanasia without 
PET imaging. The heart and brain were dissected and fixed in 10% formalin for 24–48 h. 
These tissues were processed for immunohistochemistry by being embedded in paraffin 
by the Molecular Pathology facility (Robarts Research Institute, London, ON) and cut 
into 10 μm thick sections. Care was taken to ensure that the tissues were embedded in the 
same orientation within each block. 
2.2.5.2  Immunohistochemistry Protocol  
Following a modified protocol based on Abcam standards, tissue sections were 
deparaffinized and rehydrated in a series of xylene and ethanol washes prior to heat-
mediated antigen retrieval in a citrate buffer for 30 minutes. Slides were then cooled 
slowly to room temperature, and Background Sniper (Biocare Medical) was applied for 8 
minutes to reduce nonspecific background staining. Sections were incubated overnight at 
4 ℃ with either primary anti-PBR (1:200, Abcam), primary anti-α-SMA (1:500, Abcam), 
or no antibodies—the latter acting as the positive and negative control. All antibodies 
were diluted in 1% bovine serum albumin (BSA) PBS. Following thorough washing with 
1 × PBS, Alexafluor IgG (Life Technologies, 1:500) secondary antibodies were used to 
visualize the primary antibodies: anti-PBR sections were incubated with 594 Goat anti-
rabbit IgG, and anti-α-SMA sections with 488 Goat anti-mouse IgG for 2 h at room 
temperature. For heart tissue, a solution of Cu2SO4•5H2O was applied thereafter to 
prevent red blood cell autofluorescence. Additional 1 × PBS washes and an immersion in 
0.1% Sudan Black B was performed to quench autofluorescence in both heart and brain 
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tissue sections. Lastly, ProLong Gold anti-fade with DAPI (Life Technologies) was 
added to all sections to visualize the nuclei and to mount the coverslips onto glass slides. 
2.2.5.3  Microscopy and Image Analysis  
Fluorescent images were acquired on an epifluorescence microscope (Nikon Eclipse 
Ts2R) using NIS Elements Microscope Image Software. Non-overlapping fields of view 
at 60x magnification were taken for each tissue section (n=5-10 images/slide). 
Quantitative assessment of TSPO fluorescent signal in both wild-type and mdx:utrn(+/-) 
(henceforth named DMD) subjects—while minimizing image exposure and auto-
fluorescence (i.e. background signal)—was performed using an in-house semi-automatic 
grey scale thresholding protocol in ImageJ (LOCI, Wisconsin, USA) with FIJI package 
v2.0.0 [29]. 
2.2.6 Statistical Analysis  
Analyses were performed using RStudio v1.0.136 (Boston, MA, USA) or SPSS 26 (IBM, 
Armonk, NY, USA) software. Data results are expressed as mean ± standard error (SE). 
Comparisons between groups were performed using Welch’s two-tailed t-test. No 
statistical analyses were conducted on autoradiography and biodistribution data due to 
low sample sizes. Negative biodistribution values were removed from the data set. 
Pearson correlation coefficients were calculated between [18F]FEPPA left ventricle/whole 
brain uptake, and myocardium/neural tissue histological TSPO fluorescence intensity. P-
values of less than 0.05 were considered significant. Replicate numbers are indicated in 
the figure legends. 
2.3 Results  
A total of four DMD and six healthy mice were imaged. Both healthy and DMD mice 
were both able to take up [18F]FEPPA throughout the entire body—notably binding to 
our tissues of interest, the heart and brain (Fig. 2.1). Although there were not sufficient 
tissue samples to measure differences in [18F]FEPPA binding using autoradiography and 
biodistribution, preliminary results demonstrates [18F]FEPPA activity occurring body-
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wide within the heart and brain as well as in several other tissues, such as skeletal 
muscles, aorta, diaphragm, etc. as shown in Appendix Figure A.1 and Figure A.2.  
 
Figure 2.1 [18F]FEPPA SUV images of representative 8-10 week wild-type (A, C, E) 
and age-matched Duchenne muscular dystrophy (B, D, F) mice. Coronal whole-body 
(A, B) and heart images (E, F), and axial whole brain slices (C, D) were generated from 
PET time-activity curves at 30-60 minutes (n=4-6 mice/genotype). DMD=Duchenne 
muscular dystrophy, SUV=Standardized uptake values.  
 
2.3.1 Elevation of in-vivo inflammation-targeted radiotracer binding 
in DMD models 
To assess the influence of inflammation on dystrophic cardiac and neural tissue, 
inflammation was quantified from the [18F]FEPPA PET images as mean SUV. In the 
thoracic region, left ventricle-to-lung mean SUV ratios indicated that DMD mice had 
significantly higher [18F]FEPPA uptake (Fig. 2.2; T1,7.62=2.58, P=0.0338), as these left 
ventricle-to-lung ratios increased from 0.63±0.10 in healthy mice to 0.99±0.06 in their 
DMD equivalents. In neural tissue, similar accumulations of inflammatory tracer were 
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also observed in DMD mice. Healthy brains demonstrated [18F]FEPPA uptake of 
0.34±0.08 SUV, while DMD brains experienced 45.4% more uptake at 0.62±0.08 SUV. 
 
Figure 2.2 Quantified [18F]FEPPA activity in hearts (A) and brains (B) of age-
matched DMD and wild-type mice. Standardized uptake values were generated from 
PET time-activity curves at 30-60 minutes using manually drawn regions of interest 
(ROIs) segmented for the left ventricle, lung, and whole brain (n=3-4 
slices/subject/genotype). Significant differences (p<0.05; indicated by *) were observed 
between wild-type (white bars) and DMD mice (gray bars) for both left ventricle-to-lung 
ratio (A) and whole brain (B) SUVs using Welch’s two-way t-test. Data are depicted as 
mean ± standard error. TSPO = (18kDa) Translocator protein, other abbreviations as 
described in prior figures. 
 
2.3.2 Ex-vivo TSPO signal indicates heightened cardiac and 
neuroinflammation in DMD 
Fluorescence immunostaining of heart and brain slices confirmed the presence of TSPO 
in age-matched DMD subjects. Although both groups expressed a modest baseline level 
of TSPO (Fig. 2.3); consistently, DMD mice expressed significantly higher TSPO 
fluorescence intensity in both cardiac (Fig. 2.4; T1,31.2=2.35, P=0.025) and neural tissue 
(Fig. 2.4; T1,69.2=5.15, P<0.001). Within cardiac tissue, DMD mice experienced a 63.9% 
increase in fluorescence intensity when compared to age-matched wild-type mice; as 
dystrophic hearts demonstrated TSPO fluorescence intensities of 1261.57±307.76 AU 
compared to those of wild-type mice at 454.59±63.93 AU. Similarly, in neural tissue, 
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TSPO fluorescence intensity was remarkedly 68.3% lower in healthy controls compared 
to DMD mice. Dystrophic brain tissues displayed fluorescence intensities of 
1149.74±148.35 AU, which is lower than the 364.84±73.71 AU observed in wild-type 
brains. Histological myocardium TSPO signal significantly correlated with [18F]FEPPA 
uptake in the left ventricle (Fig. 2.5; r=0.59, p=0.037). This was also observed between 
neural tissue TSPO fluorescence intensity in histology and in-vivo whole brain TSPO-
PET tracer SUV values (Fig. 2.5; r=0.57, p=0.042). 
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Figure 2.3 Ex-vivo histology of TSPO-bound microglial and macrophages in DMD 
and healthy subjects’ cardiac (A) and neural tissues (B). Representative fluorescence 
immunostained images of microglial and macrophages with TSPO (red) and DAPI (blue) 
in 8-10 week old subjects depict qualitatively more prevalent TSPO expression in DMD 
mice. White arrow heads indicate regions of TSPO signal. Scale bar= 20μm. 
Abbreviations as described in prior figures. 
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Figure 2.4 Quantified fluorescence immunohistochemical images of microglial and 
macrophages with TSPO in 8-10 week old DMD and healthy subjects. Data 
(mean±SE) depicts higher TSPO in DMD mice (gray bars) than wild-type controls (white 
bars) (n=3 mice/genotype). Significant differences (p<0.05), indicated by *, were 
observed for slices of cardiac (A) and neural (B) tissue when compared using Welch’s 
two-way t-test (n=5-10 images/subject/genotype). AU= arbitrary units. Other 
abbreviations as described in prior figures. 
 
Figure 2.5 Correlation of [18F]FEPPA uptake with histological TSPO fluorescence 
intensity. Data depicts the significant correlation of the left ventricle (A) or whole brain 
(B) SUV, with quantified TSPO myocardium or neural tissue fluorescence signal. 
Pearson product-moment correlation coefficients (r) were calculated on all PET animals 
(n=10). Significance was considered when p<0.05. Abbreviations as described in prior 
figures. 
44 
 
2.4 Discussion 
The goal of this exploratory study was to evaluate the ability of [18F]FEPPA PET as a 
tool to assess inflammation in-vivo in multiple organs of mice with dystrophic disease. 
We found dystrophin-deficient mice had elevated [18F]FEPPA uptake in cardiac and 
neural tissues compared to healthy controls, which mirrored heightened ex-vivo TSPO 
levels in our histological data. These results support our hypothesis that subjects with 
DMD demonstrate significant inflammation in their heart and brains using TSPO-PET.  
To the best of our knowledge, our study is one of the first to observe significantly 
elevated TSPO-PET in the heart and brains of DMD mice. Interestingly, these increases 
seem to be occurring body-wide within several other tissues, akin to other diseases linked 
to chronic inflammation (e.g. atherosclerosis, myocardial infarctions, etc.) [24,30,31]. As 
such, it is likely that this heightened TSPO activity may be a consequence of activated 
macrophages and microglia within regions of tissue injury or dysfunction [31]. For 
example, immunohistostaining of mice one week post-myocardial infarction indicated 
colocalization of TSPO to CD68+ microglia and cardiac monocytes within the brain 
cortex and infarcted myocardium respectively [24]. Interestingly, no colocalization was 
found between TSPO and GFAP-stained astrocytes at that time point. TSPO-tracers were 
also found to localize to magnetic resonance imaging (MRI)-identified ischemic lesions 
within ischemic stroke patients, further demonstrating the tracer’s feasibility to also map 
inflammation after incidences of tissue damage [32]. Thus, as DMD pathophysiology is 
known to be associated with contraction-induced damage and severe immune cell 
infiltration, it is likely that TSPO is upregulated within regions of injury—manifesting as 
the displayed [18F]FEPPA tracer uptake within the dystrophic heart and brain. Our 
preliminary biodistribution and autoradiography observations support these claims, as the 
TSPO-tracer accumulated notably within regions associated with DMD symptoms (i.e. 
heart, brain, skeletal muscles, etc.). Although this exploratory study demonstrated the 
feasibility of [18F]FEPPA PET to assess in-vivo inflammation simultaneously within the 
heart and the brain, our study cannot provide a definite answer to whether [18F]FEPPA 
PET can demonstrate inflammatory load within other tissues—despite the promising 
trends—due to the small sample sizes of our autoradiography and biodistribution data. To 
45 
 
answer this question, a study using a larger sample size as well as the quantification of 
tracer uptake in the other tissues within the PET data is needed.   
In contrast to our results, three previous 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) 
PET studies reported lower mean cardiac SUV and highlighted select neural regions of 
hypometabolism in DMD canine hearts and patient brains, respectively [33–35]. While 
[18F]FDG can be used as an analogue of inflammation in several neurological and cardiac 
diseases, it should be noted that these specific studies were focused on investigating the 
metabolic functionality of dystrophin-deficient tissue regions rather than its associated 
peripheral inflammation [36,37]. Because of the heart and the brain’s disposition as 
highly metabolically-active organs, there is naturally a higher accumulation of [18F]FDG 
tracer within those regions, which makes it difficult to detect inflammatory infiltrates 
within either organ without it potentially being obscured by background activity or 
alterations in myocardial/neuronal function [38,39]. Additionally, a multi-tracer study 
longitudinally tracking microglial activation and glucose hypometabolism simultaneously 
in a transgenic mouse model of Alzheimer’s disease observed discrepancies between the 
data trend of the TSPO-tracer [18F]GE-180 and [18F]FDG [40]. The authors observed 
progressive increases in [18F]GE-180 uptake throughout the entire course of the disease 
(5-16 months), which differed from the life-course kinetics of [18F]FDG which peaked at 
~8 months of age before decreasing for the remaining 8 months, suggesting that the 
incidences of hypometabolism demonstrated within the dementia subjects are occurring 
much later in life and as disease progressed. Interestingly, this early hypermetabolism 
may be capturing increased glial activity as it matches the peak of [18F]GE-180 at 8 
months—indicating the potential early onset of inflammation prior to rampant 
hypometabolism (and with it, the neurodegenerative symptoms) [41]. Taken together, 
although prior [18F]FDG studies in DMD subjects show known indications of late-life 
brain and cardiac degeneration/dysfunction, our data highlights the potential role of 
inflammation in contributing to these metabolic deficiencies within DMD mice. Further 
longitudinal multi-tracer studies on dystrophic subjects using both [18F]FEPPA and 
[18F]FDG would greatly improve our understanding of the time course and interaction of 
inflammation and glucose hypometabolism onset.  
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The increased in-vivo [18F]FEPPA activity within the heart of our DMD mice correlated 
with increases in ex-vivo histology, demonstrating that TSPO overexpression seems to be 
localized to the dystrophic myocardium. We suspect that this overexpression indicates the 
presence of inflammatory cell infiltration—presumably primarily activated 
macrophages—to the hearts of 8-10-week old dystrophic mice. Although we 
acknowledge that TSPO is known to be constitutively expressed within cardiac tissue, the 
mRNA profile of TSPO typically remains at a steady moderate state within normal 
healthy tissue [42,43]. Importantly, TSPO is found to be overexpressed in inflammatory 
cardiac foci, seemingly being upregulated in activated immune cells [44,45]. TSPO-PET 
has similarly been used as a marker of cardiac macrophage infiltration in previous studies 
of myocarditis, and myocardial infarction [24,44]. As such, it is suggested that these 
heightened [18F]FEPPA activities may indicate activated macrophage presence within the 
murine dystrophic heart.  
Macrophage recruitment to the DMD heart is not unique to this study, as the well-known 
narrative of dystrophic cardiac degeneration is centered around inflammation-exacerbated 
damage, following dystrophin-deficient cardiac muscle contraction. It is currently 
hypothesized that similar to the skeletal muscle, these high incidences of inflammation in 
DMD cardiac tissue may be the result of a longstanding contraction-induced damage 
cycle caused by dystrophin loss [4,13,46]. The lack of dystrophin protein within 
cardiomyocytes, shows increased susceptibility of the sarcolemma to damage from 
muscle contractions, resulting in a “leaky” plasma membrane [13,47]. In addition, 
dystrophin-deficient cardiomyocytes are found to have significantly impaired L-type 
calcium channels and mechanical stretch-activated receptors, which normally promote 
the influx of calcium ions from the extracellular matrix and contribute to depolarization. 
Due to impaired calcium channels, excessive calcium overflow occurs within 
cardiomyocytes, which increases reactive oxygen species and subsequently triggers the 
NF-kB signaling pathway [13,48]. This prompts the further release of inflammatory 
cytokines and the recruitment of macrophages, lymphocytes, and other cells [49]. This is 
one possible contributor of cardiac inflammation. Additionally, the improper channel 
functionality may result in the influx of excess calcium ions, activating proteases within 
the cell and initiating an auto-digestion process of the remaining myocytes, thus 
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beginning the cardiac degenerative process [13,47,48]. To help with phagocytosis, these 
necrotic cardiomyocytes may trigger the recruitment of macrophages, which can release 
pro-inflammatory cytokines. These cytokines may trigger fibroblasts in the extracellular 
matrix to produce collagen, leading to fibrosis—particularly in regions of high 
contractility and movement (e.g. left ventricle) [5,14,15]. As a result, elastic cardiac 
muscle is replaced with rigid fibrotic tissue, subsequently leading to the iconic 
cardiomyopathy associated with DMD.  
Our data, highlighting the presence of TSPO-bound ligands in DMD subjects and the 
histological evidence of M1-like (proinflammatory) and M2-like (reparative) macrophage 
infiltration into the sites of DMD injury support this hypothesis [50–52]. Interestingly, 
these suspected elevations in inflammatory load are observed quite early at 8-10 weeks—
when the mdx:utrn(+/-) model heart function is relatively stable. This agrees with earlier 
reports that indicate a certain degree of inflammation, cellular necrosis, and fibrosis 
within their myocardium at 10 weeks of age [53]. However, it should be noted that one 
cardiac DMD murine study found a lack of macrophage infiltration into cardiac tissue 
until 6 months of age—in contrast to our results [54]. This delayed inflammatory onset 
might be due to the authors’ use of mdx mice, a comparatively less severe model than 
ours, as it is known to demonstrate minimal—if any—cardiac dysfunction [55,56]. 
Within studies pertaining the same murine model as ours, evidence of ventricular 
dysfunction (i.e. impaired stroke volume, decreased ejection fraction, and elevated heart 
rate) were observed far later at 10 months of age, compared to our observed onset of 
cardiac inflammation at 8-10 weeks [57]. Thus, the present findings may indicate an early 
onset of cardiac inflammation prior to the onset of cardiac symptoms. Considering that 
mdx:utrn(+/-) mice who were started on an anti-inflammatory quercetin-enriched diet at 
8 weeks of age have comparatively minimal cardiac damage than those without, the early 
detection and intervention to modulate cardiac inflammation may be vital in possibly 
attenuating downstream DMD cardiac degenerative symptoms [58]. A more extensive 
explanation of this mechanism is outside of the scope of this paper. However, a further 
longitudinal study pairing this [18F]FEPPA PET protocol with an anatomical or 
morphological modality (such as MRI), may be undertaken to better assess how this early 
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inflammatory response may contribute to the pathology of dystrophic cardiac tissue 
damage.   
[18F]FEPPA was originally designed and is still commonly used to assess activated 
microglia, as an analogue of neuroinflammation. In-vivo [18F]FEPPA SUV has been 
correlated with post-mortem pro-inflammatory markers histologically in other 
neuroinflammatory or disease models, validating its use as an analogue of activated 
microglia cells [59]. In the current study, in-vivo [18F]FEPPA signal within the whole 
brain was found to correlate with ex-vivo TSPO immunofluorescence intensity, 
suggesting the possible localization of activated microglia to the dystrophic neural tissue. 
To the best of our knowledge, there are no other study demonstrating the presence of 
immune cell infiltration into the dystrophic brain. However in support of our 
observations, heightened levels of pro-inflammatory cytokines interleukin (IL)-1β and 
Tumor Necrosis Factor (TNF)-α (molecules commonly associated with neurological 
immune response) have been found within the brains of mdx mice, who also displayed 
cognitive impairment similar to those in DMD patients [22]. Recent literature has also 
speculated that these specific cytokines may participate in the emergence of DMD 
cognitive dysfunction symptoms by altering several features in synaptic transmission (see 
review in Rae and O’Malley [60] and Stephenson et al. [61]). Considering that activated 
microglia are known to upregulate TSPO expression and release pro-inflammatory 
cytokines (e.g. IL-1β, IL-6, TNF-α), it is possible that the activated microglia may 
contribute to the dystrophic brain’s impairment [24,62,63]. Additionally, the activated 
microglia may also predict cognitive deterioration as multiple studies regarding 
neurodegenerative diseases—such as Alzheimer’s dementia—have reported that the 
degree of neuroinflammation can predict longitudinal cognitive decline [64]. Similarly, it 
is widely accepted that the earliest manifestation of some neurodegenerative diseases is 
microgliosis, which are evident before the onset of clinical symptoms [65,66]. While the 
underlying mechanism on how activated microglia contributes to downstream 
neurodegeneration is still under debate, the early observation of neuroinflammation 
within our study and the knowledge of late-onset cognitive decline within both older 
DMD patients (occurring at 30 years of age) and aged murine models (occurring at 18 
months) suggests a possible similar association [10,12]. As such, a future study using 
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TSPO-PET to longitudinally assess neuroinflammation in these DMD murine models—
alongside cognitive testing—is suggested to better delineate the relationship between 
early neuroinflammation and late-onset cognitive decline.  
A possible explanation for this microglia activation within the brain may, in part, be due 
to pro-inflammatory cytokines—which are abundant in DMD circulation—passing 
through the “leaky” dystrophin-deficient blood-brain barrier (BBB) [4]. Within the brain, 
dystrophin—specifically Dp71—is located in the perivascular end-feet of astrocytes, 
normally participating in the stabilization and regulation of molecules transporting 
through the BBB [67]. In mdx mice, the reduction of Dp71 demonstrates severe alteration 
of endothelial and glial cells, as well as a reduction in the expression of zonula occludens 
and Aquaporin-4. As a result, mdx mice shows increased vascular permeability and by 
proxy, increased permeability of the BBB [67–69]. Increased BBB permeability and IL-6 
levels within the brain were shown when systemic inflammation was induced by a 
peripheral lipopolysaccharide injection to an Alzheimer’s APP transgenic mouse, 
resulting in more severe cognitive symptoms [70]. Thus we speculate that the nature of 
this [18F]FEPPA uptake and subsequent TSPO overexpression within the brain may be 
due a result of a similar incidence. However, it should be noted that within a study 
investigating the permeability of the BBB in mdx mice, CD4-, CD8-, CD20- and CD68-
positive cells were not histologically observed within the BBB perivascular stroma [71]. 
These observations, while contrasting, do not conflict with our findings as alternate 
passages of cytokines through the BBB has already been extensively investigated [72,73]. 
A possible source of systemic inflammation/pro-inflammatory cytokines within our study 
include the dystrophin-deficient cardiac and skeletal muscles—which as stated before are 
known to sustain critical damage upon sarcolemma contraction and release pro-
inflammatory cytokines into circulation. The concomitant TSPO-tracer uptake within 
both the heart and brain and our autoradiography and biodistribution results (i.e. trends 
towards heightened binding across almost all tissue types) speaks to the systemic nature 
of inflammation within DMD, while hinting its possible contribution to both downstream 
cardiac and neurodegeneration damage. It will be interesting to investigate if the 
neuroinflammation observed in this DMD mice model is widespread across the whole 
brain, or specific to certain regions, especially in the hippocampus where atrophy within 
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this region has been linked to progressive cognitive impairment in DMD mice [12]. 
Further PET/MRI studies linking [18F]FEPPA PET to regional MRI volumetry and 
functional MRI network changes will help shed more light.   
The strengths of our study include: 1) the utility of non-invasive inflammation imaging 
using second generation TSPO radioligand [18F]FEPPA, 2) the use of a high-resolution 
(1.4 –1.5mm) small animal PET scanner capable of multi-organ/whole-body image data 
acquisition, and 3) the showcase of tissue-specific dosimetry and molecular 
colocalization capabilities via biodistribution and autoradiography respectively in a DMD 
murine models—allowing for the additional in-vitro histopathological validation of our 
in-vivo imaging studies. However, this study also has several limitations. Firstly, the 
study sample size is relatively small and uses a mixed sex murine cohort despite DMD 
being a X-linked genetic disorder and thus, primarily appearing in only human male 
patients. While this is a common notion in DMD pre-clinical literature since both sexes 
can express this phenotype through mutations in their dystrophic and utrophin genes, 
there have been reports that female patients and rodents express constitutively higher 
levels of TSPO in both cardiac and neural tissue [56,74–76]. Due to low sample sizes, we 
could not account for these potential sex differences with this study; however, a fair 
balance between sexes were used (wild-type: 2 females, 4 males; DMD: 2 females, 2 
males). Secondly, similar to other TSPO-PET literature, [18F]FEPPA is unable to 
differentiate between macrophage/microglia morphological states (i.e. pro-inflammatory 
and anti-inflammatory). Lastly, while [18F]FEPPA is commonly used to assess activated 
microglia, it is difficult to discern the true sensitivity of this tracer within DMD as TSPO 
is also present in astrocytes, pericytes, and endothelial cells, among other structures 
within the brain at low levels. During DMD, astrocytes may be activated due to a lack of 
functional dystrophin, as its absence can precipitate a series of complex signalling 
cascades that leads to glutamate toxicity in the CNS [77]. However, it should be noted 
that the percentage of cells expressing TSPO are reported to be ~7 times higher for 
microglia than for astrocytes, as measured by scRNA-seq—suggesting a preference for 
the TSPO radiotracer to bind to microglia [78]. Thus, it is suggested that further multi-
tracer studies using both [18F]FEPPA and specific PET tracers targeting solely activated 
macrophages or microglia such as triggering receptor expressed on myeloid cells 
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(TREM) can be used to further validate the use of [18F]FEPPA as a multi-organ 
inflammation assessment tool in DMD [79].    
2.5 Conclusions 
This exploratory study demonstrated that dystrophin-deficient subjects were associated 
with higher inflammatory [18F]FEPPA radiotracer binding, mirroring ex-vivo histological 
TSPO data within both their hearts and their brains, and suggesting the presence of early-
onset cardiac- and neuroinflammation. Thus, TSPO-PET might be a useful tool for the in-
vivo assessment of chronic inflammation in several organs simultaneously, particularly 
within a dystrophic disease. 
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Chapter 3  
3 Conclusions and Future Directions 
3.1 Study Summary 
The aim of this thesis was to primarily explore the use of [18F]FEPPA PET for non-
invasive imaging of in-vivo inflammatory involvement in the heart and brain of 
mdx:utrn(+/-) mice. From this thesis, two main conclusions were reached: 1) the 
dystrophic heart and brain are associated with significant inflammation, and 2) 
[18F]FEPPA PET is able to assess multi-organ inflammatory load within murine models 
of DMD.  
We demonstrated that 8-10 week old mdx:utrn(+/-) mice had higher [18F]FEPPA uptake 
in their heart and brains compared to age-matched healthy counterparts, which correlated 
with heightened ex-vivo TSPO levels in our histological data. Preliminary 
autoradiography and biodistribution also demonstrated the potential ex-vivo use of 
[18F]FEPPA to assess inflammatory load within other organs—indicating the feasibility 
of this imaging tool as a useful multi-organ assessment tool for inflammation as a result 
of DMD.  
The heightened [18F]FEPPA uptake in the dystrophic heart may be a result of activated 
cardiac macrophage recruitment to regions of contraction-induced damage caused by 
dystrophin-loss [1]. However, we speculate that since its onset is observed far earlier than 
cardiac dysfunction (typically observed at 10 months of age in murine models), this early 
inflammatory response may contribute to the downstream pathology of dystrophic 
cardiac tissue damage. Similar incidences of heightened TSPO expression was also 
observed within the dystrophic brain, which may be the result of microglial cells 
activation. BBB disruption by a lack of dystrophin may be one of the driving causes, as 
its increased permeability leads to pro-inflammatory cytokine infiltration [2–4]. As 
activated microglia may act as both a source and target of inflammatory cytokines, it is 
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possible that the cytokine-mediated cognitive impairment hypothesis within the 
dystrophic brain can be mediated by activated microglia [3–6]. 
 
3.2 Significance 
With increased DMD patient longevity, there have been growing concerns in identifying 
and treating later onset of symptoms in other organs—specifically within the heart and 
brain—associated with the later stages of DMD [7–9]. As inflammation is reputably 
widespread within both dystrophic skeletal and cardiac muscle, and is becoming a 
growing concern within the dystrophic brain, the subsequent development of anti-
inflammatory therapies that could be implemented prior to onset of severe cardiac or 
neurological damage can be considered [1,3,10]. As such, the main significance of this 
research lies in its contribution to the better understanding of inflammation—specifically 
through providing a tool for researchers to better assess inflammatory load within 
multiple dystrophic organs at once. The use of [18F]FEPPA imaging is novel, as this work 
is the first to utilise a specific inflammatory PET tracer (TSPO) within mdx mice rather 
than using the more conventional [18F]FDG (which have only been assessed in terms of 
glucose consumption previously) [11–13]. Additionally, the use of PET in conjunction 
with autoradiography and biodistribution within our study protocol is also significant. It 
allows for assessment of inflammation on both an in-vivo (via non-invasive PET) and ex-
vivo (via autoradiography and distribution) level within one specimen, while accounting 
for potential inter-individual heterogeneity between subjects.  
Using [18F]FEPPA, inflammation is seemingly observable in dystrophic cardiac tissue at 
8-10 weeks of age, while signs of neuroinflammation were also present. The observations 
of neuroinflammation as well as the concurrent presence of cardiac inflammation within 
the dystrophic subject are novel, as they are the first to demonstrate significant TSPO-
upregulation within the dystrophic heart and brain—to which we attribute to activated 
macrophages and microglia. From these data, the potential avenue of modulating 
inflammation as a potential therapy is further emphasized. 
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3.3 Limitations 
Our findings within this thesis have profound impact in the field of DMD imaging 
research. However, as with all studies, there exists some limitations. Firstly, although we 
discussed our findings with a pro-inflammatory inclination, the inability of [18F]FEPPA 
to differentiate between pro-inflammatory M1-like and anti-inflammatory M2-like 
macrophages/microglial cells should be noted [14]. This has been an on-going concern 
for multiple inflammatory PET analogues—including all the TSPO-PET tracer series as 
well as the clinically used [18F]FDG. However, amongst a comparative study assessing 
the inflammatory cell uptake of five candidate inflammation tracers in myocardium, 
[18F]GE180—another TSPO-targeting PET tracer—showed preferential accumulations in 
pro-inflammatory M1 macrophages that was seven-fold higher than in M2 [15]. In 
addition, [18F]GE180 also showed highly selective binding to CD11b+ monocytes over 
other cell types (i.e. T-cells, natural killer cells), further demonstrating the specificity of 
TSPO-targeting radiotracers. Considering that [18F]GE180 has 20 times lowered brain 
penetration than other TSPO tracers—including [18F]PBR28, which is very similar to 
[18F]FEPPA—we can anticipate better specificity [16]. In addition, it should be noted that 
in-vivo macrophages are not merely classified into M1 or M2 subclasses, but rather will 
shift its phenotype on a spectrum towards a certain morphology depending on the signals 
they receive. As such, it is quite possible for macrophages to display a mixed phenotype, 
having both M1 and M2 characteristics [17,18]. Nonetheless, as the true aim of this was 
to assess the ability of TSPO-PET to track multi-organ inflammatory load—in which it 
does— this discrepancy does not take away from this conclusion. 
Secondly, while we have used [18F]FEPPA within this study as an analog of activated 
microglia within the brain, TSPO expression is known to come from several different 
sources. For instance, TSPO is also constitutively expressed at low levels on astrocytes, 
pericytes, endothelial cells, among other structures within the brain. These low-levels of 
expression are not anticipated to cause a discrepancy to our drawn conclusions, as TSPO 
is typically overexpressed at significantly higher levels under disease conditions.  
However, it should be noted that reactive astrocytes are also known to overexpress TSPO 
under certain conditions [19]. This is of concern within our DMD models, as the lack of 
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dystrophin can trigger a signaling cascade that results in the inhibition of effective 
glutamate clearance. As glutamate toxicity within the body can prompt astrocyte 
activation, it is possible that the overexpressed TSPO levels (and subsequent [18F]FEPPA 
uptake) within the dystrophic brain may not strictly reflect activated microglia [20,21]. 
However, within a study using scRNA-seq to assess TSPO expression within various 
neuronal cell populations, the percentage of cells expressing TSPO were reported to be 
~7 times higher for microglia than for astrocytes [22]. Thus, while TSPO expression 
seems to skew towards microglia—thereby supporting our study conclusions—the 
specificity of TSPO-radiotracer in targeting microglia should be considered in future 
studies. This is similarly an issue within the heart, as TSPO is also overexpressed by 
injured cardiomyocytes. Although its involvement is still unclear, the RNA knockout of 
TSPO in cardiomyocytes post-anoxia/reoxygenation treatment (an analogue of 
ischemic/reperfusion injury) resulted in inhibited mitochondrial ROS generation and 
decreased apoptotic cell death [23]. Initially in this thesis, there was the intention of 
validating the specificity of TSPO through histological co-staining with CD68 or 
MHCII—which are commonly expressed on activated macrophages and microglia cells 
[24,25]. Unfortunately, this was not accomplished due to restraints imposed by current 
global events, but future work in this capacity is suggested to validate the specific 
contribution of glial cells to DMD cardiac and neurologic outcomes. 
Lastly within this thesis, both male and female murine models were used. Despite DMD 
being more prominently featured in males since it is an X-linked recessive genetic 
disorder, both sexes exhibit DMD pathogenesis due to mutations in dystrophin and 
utrophin genes. This is commonplace within DMD literature, as several studies 
(including our own) use a mixed sex cohort during experimentation [26–28]. However, 
within an acute myocarditis study, females were reported to constitutively express higher 
levels of TSPO within cardiac tissue than males prior to disease onset [29]. Similarly, 
healthy female patients were found to have higher [11C]PBR28 binding across global grey 
matter, frontal, temporal, occipital and parietal cortices, hippocampus, and thalamus than 
their males counterparts [30]. Due to low sample sizes, we could not account for sex as a 
covariate within our statistical analyses; however, a fair balance between sexes were used 
(wild-type: 2 females, 4 males; DMD: 2 females, 2 males). Nonetheless, future 
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investigation towards determining the baseline TSPO levels within cardiac and neural 
tissue of dystrophic subjects is advised. 
3.4 Future Directions 
The work of this thesis has demonstrated the feasibility of [18F]FEPPA PET as a non-
invasive tool to assess multi-organ inflammatory involvement in-vivo and investigated 
the presence of inflammatory load within the dystrophic heart and brain of mdx:utrn(+/-) 
mice. While the conclusions drawn are useful to the field of inflammatory imaging as 
well as to DMD research in general, there are still additional questions to be answered.  
We demonstrated the presence of immune cells within the dystrophic heart and brain 
histologically and with PET imaging. A future area of interest is in the pairing of our 
imaging protocol with an additional modality (e.g. MRI or CT) to discern the presence of 
any anatomical or functional outcomes associated with or co-localized to inflammatory 
involvement. Histologically, in the DMD heart, inflammatory foci concentrate to regions 
of cardiac damage (i.e. tissue necrosis, fibrosis, lesions) [31]. While, some DMD boys 
have indicated signs of brain atrophy in some computed tomography (CT) and MRI scans 
[32,33]. As such, these future studies may be useful in delineating the contribution of 
activated macrophages and microglia to dystrophic cardiac and neurological 
morphological outcomes.  
As one of the major benefits of our imaging protocol is its in-vivo and minimally invasive 
nature, another future direction is the longitudinal imaging of inflammation throughout 
disease progression. Within this exploratory study, we have demonstrated the possible 
presence of inflammatory cells in DMD mice at the 8-10 week time point, despite mdx 
mice studies reporting cardiomyopathy symptoms and cognitive degeneration at 10 and 
18 months respectively [9,34]. Thus, a study longitudinally imaging mdx mice at 4-5 
weeks (immature), 8-10 weeks, 15-20 weeks (matured), and ~10 months (aged) should be 
conducted to gain a better understanding of inflammation throughout age progression. 
Our [18F]FEPPA PET protocol can also be applied to different mdx mouse models—
genetically mutated to demonstrate different disease severities—for a greater 
understanding of disease progression [28,34]. In addition, this protocol may also be 
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performed in conjunction with echocardiograms or various forms of cognitive tests to 
assess inflammation in relation to the emergence/evolution of DMD cardiac and 
neurologic functional outcomes. 
Lastly, although our sample size for the biodistribution and autoradiography analyses are 
admittedly small, its trends (in combination with our PET and histological data) 
demonstrate the feasibility of an in-vivo to ex-vivo protocol that can be used to 
systematically image inflammation. In addition to DMD, there are many other 
inflammation-associated diseases that yield multi-organ dysfunction such as: multiple 
sclerosis, rheumatoid arthritis, cardiovascular diseases, etc. [35–37]. Thus, there are 
several diseases that can utilise this [18F]FEPPA imaging protocol for a more systemic 
understanding of inflammation within several organs simultaneously on both an in-vivo 
(via non-invasive PET) as well as ex-vivo (via autoradiography and biodistribution) level. 
3.5 Concluding Remarks 
In conclusion, the results of this thesis suggest that [18F]FEPPA PET may be a feasible 
tool to assess in-vivo inflammatory load within multiple dystrophic organs 
simultaneously. Using this imaging tool, we have demonstrated that dystrophin-deficient 
mice have heightened levels of activated macrophages and microglia within their hearts 
and brains respectively—thereby supporting our hypothesis. While it is evident that 
inflammation is present within the cardiac and neural tissue of DMD subjects, further 
research is necessary to better understand the contribution of activated immune cells to 
the dysfunctional outcomes. We anticipate that [18F]FEPPA imaging may be useful in 
these endeavors.  
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Appendix B: Quantitative autoradiography and Biodistribution of 
[18F]FEPPA-injected 8-10 week old mdx:utrn (+/-) mice.  
The following data were submitted as Supplementary Material in the following 
manuscript:  
Tang JM, McClennan A, Liu L, Hadway J, Ronald J, Hicks JW, Hoffman L, Anazodo 
UC. In-vivo imaging of cardiac and neuroinflammation in Duchenne muscular dystrophy: 
a [18F]FEPPA PET study. Submitted to Neuromuscul Disord in August 2020. Under 
Review. Manuscript ID: NWD-S-20-00539.  
 
Figure. A.1. Multi-organ Biodistribution of [18F]FEPPA within murine models. Data 
(±SE) shows the differences in radiotracer uptake as across multiple tissues as the 
percentage of the injected dose per gram of the tissue (%ID/g) of DMD (black bars; n=4 
mice) and age-matched healthy controls (white bars; n=2 mice). No statistical analyses 
were conducted due to low sample sizes. DMD=Duchenne muscular dystrophy, 
[18F]FEPPA=[18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide. 
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Figure A.2. Quantified autoradiography of [18F]FEPPA activity in DMD and healthy 
mice. Data (±SE) depicts the log counts per second per millimetre squared area of 
[18F]FEPPA activity within slices of heart, brain, thoracic aorta, diaphragm, skeletal 
muscles, kidney and liver for DMD (black bars; n=3 mice) and an age-matched wild-type 
control (white bars; n=1 mouse). No statistical analyses were conducted due to low 
sample sizes. Abbreviations as described in prior figures. 
  
Appendix C: Sample sizes for imaging and histologic studies 
The following data were also submitted as Supplementary Material in the following 
manuscript:  
Tang JM, McClennan A, Liu L, Hadway J, Ronald J, Hicks JW, Hoffman L, Anazodo 
UC. In-vivo imaging of cardiac and neuroinflammation in Duchenne muscular dystrophy: 
a [18F]FEPPA PET study. Submitted to Neuromuscul Disord in August 2020. Under 
Review. Manuscript ID: NWD-S-20-00539.  
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Table A.1. Sample size for the number of unique wild-type and DMD murine subjects 
were successfully completed for each imaging and histological cohort. 
 PET Biodistribution Autoradiography Immunohistochemistry 
Wild-type 
C57Bl10 
6 2* 1 3 
DMD 
mdx:utrn(+/-) 
4 4* 3 3 
* indicates the removal of impossible biodistribution values for which measurement 
errors resulted in negative results (i.e. negative tissue weights stemming from weight of 
empty tube exceeding the weight of tube&tissue)  
Appendix D: Representative qualitative autoradiography images from 
[18F]FEPPA-injected 8-10 week old mdx:utrn (+/-) mice 
 
Image depicts autoradiography images of the heart, brain, thoracic aorta, diaphragm, 
gastrocnemius, tibialis anterior, kidney, and liver tissue excised from [18F]FEPPA-
injected murine models. The representative DMD mouse depicts higher tracer 
accumulation across all tissue compared to the healthy wild-type control. Regions of 
tissue are outlined in red. LU=light units.  
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Appendix E: Copyright Agreement for reproduction of Figure 
1.1 
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